N4Pharma launches advanced technology for drug reformulation and vaccine delivery
Derbyshire, UK, (January, 2015) – Nigel Theobald (founder and CEO) today announced the launch of two N4 Pharma advanced technologies to expedite and enable reformulation of poorly soluble drugs and to improve the effectiveness of existing vaccines. Based in Chellaston, Derbyshire, the N4Pharma proprietary technology platforms offer the potential for rapid, high multiple returns by reducing the associated risk, time and cost of developing new products for the pharmaceutical market.
Approximately 40% of existing drugs and over 90% of new drugs have problems with solubility, often resulting in poor absorption rates of these drugs into the body. Cocrys®, the N4 Pharma patented drug solubility process, significantly improves and advances the solubility of a wide range of drugs. Furthermore, Cocrys® is a commercially viable process for pharmaceutical companies as it is the only process that allows for the large scale manufacture of co-crystals using hot melt extrusion.
The second technology, Nuvac® is an innovative vaccine delivery system that loads the vaccine antigen into a nano-carrier which improves the ability of the vaccine to kill virus cells, increase antibody production and reduce the number of doses required. Often effective vaccine protection requires numerous doses and this can lead to major issues implementing vaccine programs. Through Nuvac N4Pharma is directly addressing a global public health priority for a new type of vaccine technology, something especially important for developing countries.
“Re-formulation of existing medicines is going to play a vital role for the pharmaceutical industry in the immediate future, particularly as more drugs come off patent protection,” said Nigel Theobald, founder and CEO of N4 Pharma. “N4 Pharma has the technology platforms to bring significant added value to existing drugs, offering them unique new benefits and improved patent protection. Our technology will allow us to become a leading player in the field of drug re-formulation”
Cocrys®is a patented process from the University of Bradford that creates co-crystals of drugs through hot melt extrusion. The significance of which is demonstrated through the FDA’s recent advice that co-crystals of existing drugs can be classified as drug product intermediates, thereby only needing simple bio-equivalence studies to gain regulatory approval rather than full phase 1,2 and 3 clinical trials. Cocrys has already produced improved highly soluble versions of the anti-fungal drug itraconazole and N4 Pharma has begun a development program to produce a faster acting version of sildenafil, the drug made famous by the brand Viagra. Proof of concept for Nuvac® has been established by the University of Queensland in bovine diarrhoea (BVDV) and N4 Pharma is undertaking further proof of concept studies for the hepatitis B vaccine and is investigating the use of Nuvac for antigen drug conjugates, an area which is revolutionising the treatment of cancer
CEO and founder Nigel Theobald alongside the other board members, Nigel Brooksby and Dr James Sawyer share a combined global expertise across pharma, vaccine and biotech markets. N4 Pharma is a specialist pharmaceutical company that is following a fast, low risk path to development with ideal solutions for the current challenges in the pharmaceutical market. 2015 marks a key growth opportunity for N4 Pharma as the company is working with the Ruffena Life Sciences team to actively seek investment.
- Ends -
For further information about N4 Pharma, please visit www.n4pharma.co.uk, telephone +44 (0)1332 690061 or email nigel@n4pharma.co.uk
Help employers find you! Check out all the jobs and post your resume.
